



PARKINSON'S DISEASE NEWS

<http://www.viartis.net/parkinsons.disease/news.htm>

2nd December 2012 - New research

GM1 GANGLIOSIDE CLINICAL TRIAL RESULTS

Journal of the Neurological Sciences [2012] Nov 20 [Epub ahead of print] (J.S.Schneider, S.M.Gollomp, S.Sendek, A.Colcher, F.Cambi, Wei Du)

A clinical trial was carried out to assess the symptomatic and disease-modifying effects of GM1 ganglioside in Parkinson's Disease. The authors do not know the precise mechanism of GM1 ganglioside but suggest what effects it has are "neuroprotective". Gangliosides are concentrated on cell surfaces mainly in the nervous system. They have been considered for use in neurological disorders.

For more information go to Gangliosides : <http://en.wikipedia.org/wiki/Gangliosides>

GM1 ganglioside was assessed for 120 weeks in people with Parkinson's Disease. The effects were compared to those people who delayed starting the treatment. At week 24, the early-start group had significant improvement in Parkinson's Disease motor symptoms. There was a significant worsening of scores in those people that delayed starting the treatment. At week 72 and week 120 those people taking GM1 ganglioside from the outset were better than those that did not. There was only a reduced worsening of symptoms after 120 weeks. So it was slowing deterioration rather than ridding symptoms. There were similar results in a previous study.

For more information concerning the previous study go to the Complete abstract :
<http://www.ncbi.nlm.nih.gov/pubmed/20206941>

<http://www.viartis.net/parkinsons.disease/news/121202.pdf>

mail@viartis.net

©2012 Viartis